TIDMNNN
RNS Number : 4564N
Nanosynth Group PLC
01 June 2022
1 June 2022
nanosynth group plc
("nanosynth", the "Company" or the "Group")
Strategy Update
nanosynth, the AIM quoted company specialising in the synthesis
and application of nanoparticles to create new and improve existing
products, announces that the Company has conducted a strategic
review and, based on recent research and development undertaken, it
has identified seven new verticals in which the Company intends to
focus on licensing its nanoparticle technology.
The verticals and areas in which the Company will be focussing
are based on significant market research and feedback from
potential customers. They include:
1. Animal Heath & Wellbeing (improved bioavailability / uptake of dietary minerals and vitamins)
1. Ruminant supplements - sheep and cattle (dairy and beef)
2. Monogastric supplements - pigs and chickens
3. Piglets - veterinarian treatments
4. Insects - enriched protean (animal feed and human)
5. Snails - protein, caviar and mucin (cosmetic ingredient)
6. Companion animals - enriched pet food and veterinarian treatments
7. Equine - enhanced fertility and performance (pre and post exercise)
2. Cosmetics
1. Sunscreen - mineral based sun protection
2. Hair Care - dermatological treatment
3. Pigments - makeup
3. Medical
1. Vitamin supplements - enhance biocapacity / uptake and performance (tablets, gels, etc)
2. Medical supplements - treatment of acute deficiencies (intravenous - bags and injections)
3. Lateral flow testing - used to produce the indicator "line"
4. Topological treatments - delivery though the skin (e.g. pain
relief, muscle recovery, and treatment of skin cancer via localised
hyperthermia)
5. Medical imaging - contrast agents in CT and MRI scanners to
show up cancer tumours, brain aneurisms etc
6. Chemotherapy - cancer treatments (e.g. Glioblastoma / brain tumour)
7. Targeted drug delivery - onsite delivery of the drug to the
site of action (e.g. cancer tumour thereby reducing side
effects)
8. Cataracts nonsurgical treatment and prevention - via
antiglycation can be delivered as eye drops, injection or part of a
contact lens
4. Plants
1. Fertilizer - improved yields, shorter harvests and higher
nutritional value for commercial farming (crops, ornamental and
medical)
2. Seed coating - improved germination and enhanced vigour for commercial farming
3. Domestic plant food - improved yields, shorter harvests and higher nutritional value
4. Citrus Greening treatment and prevention - biocide for commercial farming
5. Xylella treatment and prevention - biocide treatment for commercial farming
6. Verticillium treatment and prevention - biocide treatment for commercial farming
5. Food & Drink (improved bioavailability / uptake of dietary minerals and vitamins)
1. Breakfast cereals - enriched nutrients
2. Fortified flour - enriched nutrients
3. Baked products - enriched nutrients (e.g. bread, biscuits etc)
4. Pasta - enriched nutrients
5. Hot beverages - enriched nutritional value (e.g. iron)
6. Sports nutrition - pre and post exercise
6. Functional Coatings
1. Antipathogenic Respirators - follows on from the face masks
and air filtration (for example gas masks and medical filters)
2. Functional Paints - e.g. antiviral and antibacterial
additives, catalytic breakdown of pollutants (e.g.
formaldehyde)
3. Antipathogenic coatings - added into plastics (e.g. laminated
wood, door handles, automotive parts, storage containers) and
textiles (e.g. clothing, hazmat suit, soft furnishings,
bedding)
4. Catalytic converters - for the automotive industry
7. Electronics
1. LED Phosphors - to fine tune the wavelength emission of the light
2. Semiconductors - e.g. printable electronics, quantum dots
3. Batteries - including printable batteries
The 37 Research & Development projects in the identified
vertical markets have all been packaged into individual business
cases. The Company's lawyers are currently ensuring that the
appropriate patents are applied for in each of the seven vertical
markets and business development initiatives with clients that have
expressed significant interest are being pursued. The Company is
planning to offer an opportunity to partner on the individual
projects, while retaining its core patented technology, enabling
the clients to enhance their IP through the partnership. The
Company plans to cover the commercial cost through the development
phase through a model whereby the partnering client is charged for
development work packages. The Company's commercial strategy will
be to take either a royalty on the product sold by the partnering
client or the Company will supply relevant nano material to the
client for the project on an exclusive basis.
There can be no certainty at this stage that any of the
discussions will result in partnerships on any of the individual
projects however the Company is actively seeking to progress these
opportunities and will provide further updates to the market as
appropriate.
Mark Duffin, Chief Executive of nanosynth, commented: "As a
Company, we are extremely excited about the significant market
sectors that have expressed an interest in adopting our technology
which is expected to take us from a licensing business model into
the development, production and supply of nanoparticles."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has
been incorporated into UK law by the European Union (Withdrawal)
Act 2018. Upon the publication of this announcement via Regulatory
Information Service ('RIS'), this inside is now considered to be in
the public domain.
ENQUIRIES :
nanosynth group plc via IFC Advisory
Mark Duffin (Chief Executive
Officer)
SP Angel Corporate Finance LLP
Nominated Adviser and Broker
Stuart Gledhill
Caroline Rowe +44 20 3470 0470
IFC Advisory Ltd
Graham Herring
Zach Cohen +44 20 3934 6630
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDFLFSEELILVIF
(END) Dow Jones Newswires
June 01, 2022 02:02 ET (06:02 GMT)
Nanosynth (LSE:NNN)
Historical Stock Chart
From May 2024 to Jun 2024
Nanosynth (LSE:NNN)
Historical Stock Chart
From Jun 2023 to Jun 2024